Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
BrainAurora Medical Technology HK$583 million IPO
We advised BrainAurora on its IPO and HKEX listing
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition
Olema Pharmaceuticals $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Precigen $79 million preferred stock and warrants offering
We advised Precigen on the private placement
Personalis $50 million at-the-market offering
The shares are listed on the Nasdaq Global Market
FTC clearance of Novo Nordisk acquisition of certain Catalent sites
We secured regulatory approval following a lengthy review
Revolution Medicines $750 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Cross Country Healthcare $615 million acquisition by Aya Healthcare
We are advising Cross Country Healthcare on the transaction